1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,

Slides:

Advertisements

Similar presentations

Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.

Advertisements

Adverse Events and Serious Adverse Events

1 FDA/CDRH PUBLIC MEETING; Blood Glucose Meters FDA/CDRH PUBLIC MEETING; Blood Glucose Meters FDA Perspective: Regulatory Challenges for Safe use of Blood.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Drug Utilization Review (DUR)

1 FDA/CDRH PUBLIC MEETING: Blood Glucose Meters FDA/CDRH PUBLIC MEETING: Blood Glucose Meters FDA Perspective - Public Health Notification: Potentially.

Pramlintide Acetate Safety Review Dragos Roman MD Center for Drug Evaluation and Research.

Introduction to Regulation

The Nature of Errors Richard M. Satava, MD FACS Professor of Surgery University of Washington School of Medicine and Program Manager, Advanced Biomedical.

Introduction to Occupational Safety and Health An Approach to addressing injuries and illnesses at work.

Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.

Basic Pharmacovigilance Training

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.

FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’

The False Interpretation of Maltose as Glucose by Some Types of Glucose Testing Systems Octapharma’s Response to Ensure Patient Safety.

CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Serious adverse events following falsely high glucose measurements resulting from administration of an IGIV product containing maltose L. Ross Pierce,

Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.

Afrezza® – inhaled human insulin

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.

SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.

What Makes a Good Medical Device Adverse Event Report?

Sugar control in Critical care unit Senior clinical pharmacist : Lihua Fang Koo Foundation Cancer Center.

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.

Intensive versus Conventional Glucose Control in Critical Ill Patients N Engl J Med 2009; 360: 雙和醫院劉慧萍藥師.

Preparing for Vaccine Administration: Warnings, Precautions and Contraindications Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious.

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Occupational Medicine Recognized Specialty Since 1949 Combines Clinical Skills With Toxicology, Epidemiology, Safety, Rehabilitation, and Business Operations.

3/3/2010Handshake to Success Crescent Healthcare is a premier infusion company founded in 1992 to provide home infusion services to patients with chronic.

Improving Patient Outcomes GLYCEMIC CONTROL IN PERI-OPERATIVE PATIENTS UTILIZING INSULIN INFUSION PROTOCOLS.

Diabetes mellitus organization of care the experience of Syria Bassam ABDULMASSIH MD Endocrinologist Istanbul Friday,April

Department of Health and Human Services Office of the Assistant Secretary for Health (ASH) Advisory Committee on Blood Safety and Availability (ACBSA)

Achieving Glycemic Control in the Hospital Setting Part 4 of 4.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

1 Module 7 Discharge Planning Managing the Transition from Inpatient to Outpatient Care Diabetes Special Interest Group Georgia Hospital Association.

FDA Regulation of Prescription Drug Promotion Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.

Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA Part 4.

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.

Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.

Managing Hospital Safety: Common Safety Concerns Part 1 of 4.

Focus Area 17: Medical Product Safety Progress Review November 5, 2003.

The National Electronic Injury Surveillance System: Cooperative Adverse Drug Events Surveillance System (NEISS-CADES) Aaron B. Mendelsohn, PhD, MPH Office.

Mary Gardner, RN, MA, CCM, CDE Program Manager, High Risk Diabetes and COPD XLHealth Member Management Using The Med-eXpert System and Med-eMonitor Patient.

1 Mosby items and derived items © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier, Inc. Nursing Management: Nutritional Problems Chapter 40.

Around one million people in the UK \on insulin injections to control levels of glucose Statistics show there have been 3,931 serious incidents involving.

EAE Training PROTOCOL SPECIFIC Objectives  Definitions  Assessment of Adverse Events  EAE Reporting.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

1 Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia and/or Hemoglobinuria following Rh o (D) Immune Globulin Intravenous Administration.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.

Strategies to Reduce Hypoglycemia Presented by: Hennie Garza, M.S., R.Ph., C.D.E, Director of Pharmacy Utilization and Outcomes Senior Care Centers

Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.

Intersecting roles CMS and FDA – implications for pharmaceutical and device industries Peter B. Bach, MD, MAPP Senior Adviser, Office of the Administrator.

Glycemia Treatment Strategies Used In ACCORD

Post-bariatric Surgery Hypoglycemia : A Descriptive Analysis

FHIR Adverse Event Resource

SERIOUS ADVERSE EVENTS REPORTING

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Tobey Clark, Director*, Burlington USA

QUALITY: SAFE CARE Potentially Preventable Adverse Events and Complications of Care in Hospitals Among Medicare Beneficiaries, 2004–2005 Percent *Surgical.

Presentation transcript:

1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting, Gaithersburg, MD, November 4, 2005

2 Adverse Event Case Report Summary Ann Gaines, PhD, MT(ASCP) Division of Epidemiology Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research BPAC Meeting, Gaithersburg, MD, November 4, 2005

3 Artifactual Hyperglycemia Falsely increased glucose results may occur in patients:  Who receive parenteral maltose-, parenteral galactose-, or oral d-xylose-containing biologic and drug products.  When blood glucose levels are measured by methodologies that are non-specific for glucose in presence of maltose-, galactose-, or d-xylose- containing products.

4 Clinical Consequence Falsely elevated glucose results due to maltose, galactose, or d-xylose may result in life-threatening or fatal hypoglycemia when:  Insulin is inappropriately administered for artifactual hyperglycemia, e.g.,  glucose-non-specific methodology = 231 mg/dL, yet  glucose-specific methodology = 84 mg/dL.  Treatment is not provided for actual hypoglycemia, e.g.,  glucose-non-specific methodology = 167 mg/dL, yet  glucose-specific methodology = 41 mg/dL.

5 Case Reports CBER is aware of 6 case reports involving maltose- containing intravenous immune globulin products and falsely elevated blood glucose measurements. Case Location Year Outcome 1 U.S. 2005Fatal 2 U.K. 2002Fatal 3 France 2003Resolved 4 France 2003Resolved 5 Australia 2004Resolved 6 Australia 2004Resolved

6 Case Report year-old male patient with complicated medical history, including diabetes. + Admitted with 4-day history of cellulitis of foot. + Received OCTAGAM* for treatment of septic shock. + Experienced complicated hospital course. + Monitored blood glucose levels [and adjusted insulin doses] primarily with glucose non-specific methodology. +Became hypoglycemic then comatose. +Expired. * IGIV manufactured by Octapharma; contains 10% maltose.

7 Case Report 1 (continued) Blood glucose levels in conjunction with OCTAGAM administration

8 Case Report 1 (continued) Blood glucose levels in conjunction with insulin administration

9 Case Report 2 Reported to the Medicines and Healthcare Products Regulatory Agency (U.K.) in 2002: + 50-year-old diabetic male with failing pancreas-renal transplant received OCTAGAM as anti-rejection agent. + Based on artifactual hyperglycemia, inappropriate insulin administered. + Developed severe hypoglycemia, became comatose, expired.

10 Case Reports 3 and 4 Reported to the French Health Products Safety Agency in 2003; both cases involved 3-week-old non-diabetic males: + Received OCTAGAM for unknown indications. + Developed artifactual hyperglycemia. + Recognized or resolved without intervention.

11 Case Reports 5 and 6 Reported in Medical Journal of Australia in 2004: + 64-year-old diabetic female on dialysis received Intragam P* for ITP:  developed artifactual hyperglycemia.  increased insulin administered.  developed actual hypoglycemia.  resolved without apparent sequelae year-old non-diabetic female on parenteral nutrition received Intragam P* for ITP:  developed artifactual hyperglycemia.  recognized and resolved without intervention. * IGIV manufactured by CSL Limited; contains 10% maltose

12 Unknown Frequency of Adverse Event +FDA’s adverse event surveillance for licensed products uses primarily passive surveillance. +Limitations of passive surveillance systems, such as FDA’s MedWatch (e.g., voluntary reporting). +Actual incidence rate of artifactual hyperglycemia adverse event (e.g., occurrences per 100,000 patients) unknown. +Estimated reporting rate of artifactual hyperglycemia adverse event (e.g., reports per 1,000,000 prescriptions) unknown.

13 Adverse Event Reporting Physicians, other health care professionals, and patients encouraged to submit serious adverse event reports for any FDA-approved product:  Directly to FDA:  by Internet at  by telephone at FDA  by fax at FDA  by mail at MedWatch, HF-2, 5600 Fishers Lane, Rockville, MD To FDA through manufacturers or distributors: contact information generally available in professional package inserts or on web sites.